PEG MGF (2 mg Vial) Dosage Protocol

PEG MGF (2 mg Vial) Dosage Protocol

PEG MGF (2 mg Vial) peptide vial

Quickstart Highlights

PEG MGF is a pegylated variant of mechano-growth factor, a muscle-derived IGF-1 splice isoform that is upregulated after mechanical stress or injury[2]. The unique C-terminal E peptide of MGF activates muscle satellite cells and local protein synthesis, initiating tissue repair and growth in addition to IGF-1 receptor signaling[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water (max vial capacity) → ~0.667 mg/mL concentration.
  • Typical daily range: 200–500 mcg once daily (gradual titration over 8 weeks).
  • Easy measuring: At 0.667 mg/mL, 1 unit = 0.01 mL ≈ 6.67 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~0.667 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg 30 units (0.30 mL)
Weeks 3–4 300 mcg 45 units (0.45 mL)
Weeks 5–6 400 mcg 60 units (0.60 mL)
Weeks 7–8 500 mcg 75 units (0.75 mL)

Frequency: Inject once daily subcutaneously. Pegylation extends MGF’s half-life, allowing systemic once-daily SC dosing instead of frequent intramuscular injections[7]. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection volumes easy to measure accurately on standard insulin syringes.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (PEG MGF, 2 mg each):

    • 8 weeks ≈ 10 vials
    • 12 weeks ≈ 17 vials
    • 16 weeks ≈ 24 vials
  • Insulin Syringes (U-100):

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

    • 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
    • 12 weeks (17 vials): 51 mL → 6 × 10 mL bottles
    • 16 weeks (24 vials): 72 mL → 8 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

PEG MGF (2 mg Vial) peptide vial View Supplier
Insulin Syringes for subcutaneous peptide injection View Supplier
Bacteriostatic water 10ml for peptide reconstitution View Supplier
EasyTouch alcohol prep pads for injection site sterilization View Supplier

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support muscle recovery and regeneration through MGF’s satellite cell activation and local growth factor signaling[7][8].
  • Schedule: Daily subcutaneous injections for 8 weeks (extend to 12–16 weeks if desired).
  • Dose Range: 200–500 mcg daily with gradual titration.
  • Reconstitution: 3.0 mL per 2 mg vial (~0.667 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach based on preclinical research protocols[4][7].

  • Start: 200 mcg daily; increase by ~100 mcg every 2 weeks as tolerated.
  • Target: 400–500 mcg daily by Weeks 5–8.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8 weeks; optional extension to 12–16 weeks.
  • Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality and bioactivity[12].

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • No clinical trials of PEG MGF have been completed; effects have been demonstrated in animal and cell models only.

How This Works

MGF is a splice variant of IGF-1 that is expressed in muscle tissue following mechanical loading or damage[2]. Unlike systemic IGF-1, MGF acts locally to activate satellite cells and initiate muscle repair processes through its unique C-terminal E peptide domain. Pegylation of MGF extends its half-life, allowing for once-daily subcutaneous administration instead of the frequent local injections required for native MGF. Animal studies have shown that MGF analogues can enhance muscle regeneration, bone healing, and cartilage repair when administered over several weeks.

Potential Benefits & Side Effects

Observations from preclinical and cell-based research.

  • Animal studies demonstrate enhanced muscle, bone, and cartilage regeneration with MGF analogues administered over multiple weeks[4][6].
  • MGF promotes myogenic precursor cell proliferation and improves muscle repair in models of injury or depletion[6][7].
  • No human clinical trials have been completed; safety and efficacy in humans remain unestablished.
  • Generally well tolerated in preclinical models; mild injection-site reactions may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for optimal muscle recovery and adaptation.

  • Combine with progressive resistance training to maximize muscle growth signals and satellite cell activation.
  • Maintain adequate protein intake (1.6–2.2 g/kg body weight daily) to support muscle protein synthesis.
  • Prioritize sleep (7–9 hours nightly) and manage training stress to optimize recovery and adaptation.
  • Consider timing around training sessions, though optimal timing has not been established in human studies.

Injection Technique

General subcutaneous guidance from clinical best-practice resources[9][10][11].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
  • Do not aspirate for subcutaneous injections; inject slowly and steadily.
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and tissue irritation.
  • Always use a new sterile needle and syringe for each injection; dispose of sharps in proper containers.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • Pure Lab Peptides
    — PEG MGF (2 mg) product page (quality and batch documentation)
    View Source

  • Physiological Society
    — MGF: a local growth factor or a local tissue repair factor?
    View Source

  • In Vivo (PubMed)
    — Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro
    View Source

  • International Orthopaedics (PubMed)
    — Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits
    View Source

  • American Journal of Transplantation (PubMed)
    — A synthetic mechano growth factor E peptide enhances myogenic precursor cell transplantation success
    View Source

  • Frontiers in Physiology (PubMed)
    — Impaired skeletal muscle regeneration induced by macrophage depletion could be partly ameliorated by MGF injection
    View Source

  • Cureus
    — Peptide Therapy (News article on Mechano-Growth Factor)
    View Source

  • Rapid Communications in Mass Spectrometry (PubMed)
    — Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products
    View Source

  • CDC
    — Chapter 6: Vaccine Administration (Epidemiology and Prevention of Vaccine-Preventable Diseases, 14th ed.)
    View Source

  • Cleveland Clinic
    — Lipohypertrophy: Symptoms, Causes, Treatment & Prevention
    View Source

  • East Carolina University College of Nursing
    — Administering Subcutaneous Injections (Clinical Nursing Skills)
    View Source

  • Bachem
    — Handling and Storage Guidelines for Peptides
    View Source